It’s been a while since we last wrote on our Blog, but after several months redeveloping our Website, we are back and ready to keep the posts rolling.

For those of you who aren’t familiar with us, we are a biotech company based in Boca Raton, Florida. We’re developing treatments for neurological and autoimmune disorders, including Multiple Sclerosis and HIV. Through our subsidiary, Designer Diagnostics, we are also marketing and selling rapid test kits for Tuberculosis and Nontuberculous Mycobacterium – both leading causes of death in HIV and AIDS patients.

Over the past couple of months, we have made several upgrades to our existing Website. In addition, we’ve updated our logo and have developed a mini-logo that you will soon see scattered throughout our marketing materials and websites.

As a younger R&D level biotechnology company, we work in a faster-paced environment than most businesses. Because of this, we don’t believe that press releases, no matter how frequent, adequately keep you updated on our progress. That’s why we created this Blog to fill in the gaps.

Going forward, you’ll be hearing from Rik Deitsch, Paul Reid, Neil Roth and me, David Isserman. I’ve been involved with the Company since late-2002 and most Nutra Pharma shareholders already know me. But for those of you who don’t, I’ve included my bio below.

Before I forget, make sure that you sign up for our E-Alerts. This will ensure that you receive our press releases as soon as they are posted. We promise not to spam you or share your contact information with others. Also, if you have an interest in receiving our blog postings by email or through our RSS feed, you may sign up for that by visiting our FeedBurner page. 

Thanks to all of you who have supported us over the past several years and to those of you who recently joined the Nutra Pharma family.  Your support has enabled us to continue to grow and move forward with our clinical trials. We very much look forward to creating long-lasting and successful partnerships with each and every one of you…our shareholders.

- David
David {at} nutrapharma.com

David Isserman
David Isserman joined Nutra Pharma as an outside web development and communications consultant in 2002. In 2005, he stepped into the role as Director of Corporate and Shareholder Relations. Prior to joining Nutra Pharma, David founded Isserman Consulting, a successful communications consultancy that advises early-stage and growth companies. Before that, he was a co-founder of The Selling Block, a company specializing in asset liquidation for businesses, which he sold in 2006. David holds a Bachelor’s in Business from the Indiana University Kelley School of Business. When David isn’t working on Nutra Pharma, you can find him on the hiking trails around Boulder or volunteering his time to support wilderness conservation initiatives.

SEC Disclaimer
This article contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The above article, " Hello Again from Nutra Pharma!", should not be construed as an indication in any way whatsoever of: (a) the Company’s financial value; and/or (b) any predictive value of the Company’s future stock price. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

               

Comments

No comments yet.

RSS feed for comments on this post.

TrackBack URL

Leave a Comment

Name (required)

Email (will not be published) (required)

Website